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Summary
Background Pertussis vaccination has been alleged to cause an encephalopathy that involves seizures and subsequent 
intellectual disability. In a previous retrospective study, 11 of 14 patients with so-called vaccine encephalopathy had 
Dravet syndrome that was associated with de-novo mutations of the sodium channel gene SCN1A. In this study, we 
aimed to establish whether the apparent association of Dravet syndrome with vaccination was caused by recall bias 
and, if not, whether vaccination aﬀ ected the onset or outcome of the disorder.
Methods We retrospectively studied patients with Dravet syndrome who had mutations in SCN1A, whose ﬁ rst seizure 
was a convulsion, and for whom validated source data were available. We analysed medical and vaccination records to 
investigate whether there was an association between vaccination and onset of seizures in these patients. Patients 
were separated into two groups according to whether seizure onset occurred shortly after vaccination (vaccination-
proximate group) or not (vaccination-distant group). We compared clinical features, intellectual outcome, and type of 
SCN1A mutation between the groups.
Findings Dates of vaccination and seizure onset were available from source records for 40 patients. We identiﬁ ed a 
peak in the number of patients who had seizure onset within 2 days after vaccination. Thus, patients who had seizure 
onset on the day of or the day after vaccination (n=12) were included in the vaccination-proximate group and those 
who had seizure onset 2  days or more after vaccination (n=25) or before vaccination (n=3) were included in the 
vaccination-distant group. Mean age at seizure onset was 18·4 weeks (SD 5·9) in the vaccination-proximate group 
and 26·2 weeks (8·1) in the vaccination-distant group (diﬀ erence 7·8 weeks, 95% CI 2·6–13·1; p=0·004). There were 
no diﬀ erences in intellectual outcome, subsequent seizure type, or mutation type between the two groups (all p values 
>0·3). Furthermore, in a post-hoc analysis, intellectual outcome did not diﬀ er between patients who received 
vaccinations after seizure onset and those who did not. 
Interpretation Vaccination might trigger earlier onset of Dravet syndrome in children who, because of an SCN1A 
mutation, are destined to develop the disease. However, vaccination should not be withheld from children with 
SCN1A mutations because we found no evidence that vaccinations before or after disease onset aﬀ ect outcome.
Funding Australian National Health and Medical Research Council. 
Introduction
Claims of causal associations between vaccination and 
neurological disorders, most recently autism, have 
societal consequences for vaccination uptake and also 
have medicolegal implications.1 Despite extensive 
epidemiological studies showing no relation between 
vaccination and permanent neurological disease,1–4 
perception of causality is hard to eliminate.
In a retrospective study, most patients with suspected 
so-called vaccine encephalopathy—a poorly deﬁ ned 
disorder that causes seizures and intellectual impairment 
in infants, with onset after vaccination—had clinical 
features typical of the severe epileptic encephalopathy 
Dravet syndrome.5 Moreover, most patients had de-novo 
mutations of the sodium channel gene SCN1A, thus 
questioning the idea that the vaccination was the primary 
cause of the encephalopathy. We therefore concluded 
that in these patients Dravet syndrome was misinterpreted 
as a syndrome that had an acquired cause (vaccination) 
because the phenotype was not recognised and a family 
history of epilepsy was absent. Pertussis vaccination was 
usually suspected to be the cause of seizures and 
intellectual disability because the vaccination often 
causes minor distress (including fever and irritability, 
particularly with the old cellular preparation)6 and carries 
an increased risk of benign febrile seizures.6,7 The absence 
of family history, and severe illness in a previously healthy 
infant, reinforced the misconception that pertussis 
vaccination caused the encephalopathy. 
Dravet syndrome (also known as severe myoclonic 
epilepsy of infancy; SMEI) is characterised by onset of 
seizures at around 6 months of age. Initial seizures are 
usually prolonged convulsions, either generalised or 
hemiclonic, often triggered by fever. Other seizure types 
that subsequently develop include myoclonic, partial, 
absence, and atonic seizures. From the second year of 
life, intellectual development in these infants begins to 
plateau or regress, resulting in intellectual disability.8 
About 70–80% of children with Dravet syndrome have 
mutations in SCN1A, of which 95% are de novo.9–11 
Diphtheria-tetanus-pertussis (DTP) vaccination, typically 
given at 2 months, 4 months, and 6 months of age, has 
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been reported to precede the onset of Dravet syndrome 
or to apparently trigger further seizures in children who 
already have the disorder.8,12 In this setting, families 
typically blame vaccination for the illness. Further 
vaccination might be advised against by the physician or 
refused by the family. 
Although our earlier report suggested that vaccine 
encephalopathy was not a real disorder,5 there remains a 
possibility, because of the apparent temporal association, 
that DTP vaccination might sometimes trigger the onset of 
Dravet syndrome. Reports from families of aﬀ ected 
children might be subject to recall bias because families 
might suspect an association between the onset of Dravet 
syndrome and vaccination. If, however, the observation of 
the temporal association is valid, a gene–environment 
interaction might be occurring. 
We aimed to assess, in patients with Dravet syndrome 
and a known mutation of SCN1A, whether there was a 
genuine temporal association of seizure onset with 
vaccination, by use of source records to avoid recall bias. 
We also assessed whether patients who had onset of Dravet 
syndrome shortly after vaccination had any speciﬁ c 
clinical, molecular, or outcome diﬀ erences that could 
suggest the disorder in these patients represents a separate 
entity. Such data might have important consequences for 
the advice given to parents regarding vaccination.
Methods
Patients
We included patients with Dravet syndrome from our 
study on infantile epileptic encephalopathies.10 The 
diagnosis of Dravet syndrome includes patients who 
were previously diagnosed with classical SMEI or the 
borderline variant (severe myoclonic epilepsy of infancy 
borderline), in which certain features deemed to be 
essential for a diagnosis of SMEI are absent.10 We sought 
validated source data (the date of the ﬁ rst seizure and the 
dates of vaccinations) for patients with Dravet syndrome 
who have a mutation in SCN1A and in whom the ﬁ rst 
seizure was a convulsion. We excluded patients whose 
ﬁ rst seizure was a myoclonic or absence seizure because 
the exact dates of these are hard to verify. 
The study was approved by the Human Research Ethics 
Committee of Austin Health. Written informed consent 
was obtained from all patients or their parents at 
enrolment in our previous study. 10 
Procedures
The date of each ﬁ rst seizure was validated by use of 
hospital charts or ﬁ les from the patients’ family doctor or 
specialist. Exact dates of each of the DTP vaccinations 
were obtained from original medical records or the 
child’s health-care booklet, which was retained by the 
parents. These booklets were stamped or signed and 
dated at the time of the vaccination by the health-care 
professional who gave the vaccine. Because the exact 
composition of vaccinations has changed over time, we 
documented whether the patients received whole-cell or 
acellular forms of pertussis vaccine.
From the source data we assessed the number of days 
between the ﬁ rst convulsive seizure and the previous 
vaccination. A day was deﬁ ned as midnight to midnight 
because the date but not the time of vaccination was 
documented in the source data. The day of vaccination 
was day 0, and all seizures that occurred on day 0 occurred 
between the time of vaccination and midnight of the day 
of vaccination. Day 1 was from midnight of the day of 
vaccination to midnight of the next day. We separated 
patients into two groups according to whether seizure 
onset occurred shortly after vaccination (vaccination-
proximate group) or not (vaccination-distant group). 
We analysed the clinical characteristics and distribution 
of molecular lesions in the two groups to establish whether 
the vaccination-proximate group had a diﬀ erent outcome 
or other distinguishing clinical or molecular features 
compared with the vaccination-distant group. Intellectual 
outcome was classiﬁ ed, according to a detailed assessment 
of developmental milestones and present functioning of 
each patient, as normal intellect (documented normal 
educational achievement), mild intellectual disability 
(deﬁ nite mild intellectual impairment), moderate 
intellectual disability (limited speech and cognition but 
able to do some aspects of daily living), or severe 
intellectual disability (limited or no speech and dependent 
for activities of daily living—ie, going to the toilet and 
dressing).10 Classiﬁ cation was done by assessors masked 
to mutation type or relation to vaccination. For binary 
analyses, we grouped together children with normal 
intellect and mild intellectual disability and compared 
them with those with moderate or severe intellectual 
disability. Intellectual regression was deﬁ ned as prolonged 
(4 weeks or more) or permanent loss of skills and was 
coded as present or absent.
Numbering of SCN1A mutations was taken from the 
start codon ATG of the full-length SCN1A mRNA 
sequence (Genbank accession number AB093548). 
Mutations were divided into missense mutations or 
others from which markedly abnormal protein was 
predicted, including truncation, frameshift, and splice-
site mutations. Such other mutations have been reported 
only in patients with Dravet syndrome or related severe 
epilepsies and never in control individuals.13 Missense 
mutations were classed as causative if they had been 
previously reported in Dravet syndrome or if they predict 
a non-conservative amino acid change in an evolutionarily 
conserved residue and are absent from single nucleotide 
polymorphism databases of healthy individuals. Certain 
missense mutations cause milder epilepsy syndromes 
and rarely some missense variants occur in healthy 
individuals.13
To establish whether outcome was worse in patients 
who received vaccination after seizure onset, we 
compared outcomes according to whether or not patients 
had received further vaccinations. 
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In a post-hoc analysis, we examined whether non-
missense mutations were associated with earlier age at 
onset, and whether these mutations or earlier age at 
onset were associated with worse outcome. 
Statistical analysis
Patients with missing data were excluded from the 
relevant analyses. Independent-sample t tests were done 
to examine diﬀ erences in age at onset. Diﬀ erences in 
other characteristics between groups were tested using 
the Fisher’s exact test. Statistical signiﬁ cance was tested 
at the 5% level using two-tailed tests. All analyses not 
stated as post-hoc were prespeciﬁ ed. The number of days 
used to deﬁ ne the vaccination-proximate group was 
calculated after viewing the summary data but before the 
analyses were undertaken.
Role of the funding source
The sponsor had no role in the study design, data 
collection, data analysis, interpretation of the data, or 
writing of the report, and was not involved in the decision 
to submit the paper for publication. AMM, JMc, IES, and 
SFB had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication. 
Results
We identiﬁ ed 127 patients with Dravet syndrome from 
our previous study,10 101 of whom had a conﬁ rmed 
mutation in SCN1A. Six of these patients were excluded 
because their ﬁ rst seizure was a myoclonic or absence 
seizure. Data for 84 of these 95 patients have been 
published previously.5,10,14–16
Validated data (ie, the date of the ﬁ rst convulsion and 
the vaccination dates) were obtained from source data 
and were available for 40 of the 95 patients, including 
six patients from our earlier report on vaccine 
encephalopathy.5 The 40 patients with validated data did 
not diﬀ er from the 55 patients without validated data in 
terms of mean age at onset, outcome, syndromic 
diagnoses, or mutation types (data not shown).
The 40 patients with validated data had a median age of 
5·4 years (IQR 3·2–8·0 years; range 11 months to 27 years) 
at assessment. Mean age at seizure onset was 5·5 months 
(SD 1·9). The median age was 2·1 months (IQR 1·9–2·5) 
at the ﬁ rst vaccination, 4·3 months (4·1–4·8) at the second 
vaccination, and 6·8  months (6·2–8·7) at the third 
vaccination. Three patients had their ﬁ rst seizure before 
their ﬁ rst vaccination; the remaining 37 had their ﬁ rst 
seizure after at least one DTP vaccination. Inspection of 
these data showed a clear temporal peak (ﬁ gure 1), which 
led us to classify children as vaccination-proximate if they 
had their ﬁ rst seizure on days 0 or 1, and vaccination-
distant if their ﬁ rst seizure occurred 2 days or more after 
a vaccination. 12 of 40 patients had seizure onset either on 
the day of vaccination (n=5) or during the ﬁ rst day post-
vaccination (n=7) and were thus deﬁ ned as vaccination-
proximate. The patients in the vaccination-distant group 
had seizure onset from day 2 to day 98 after vaccination 
(n=25) or before the ﬁ rst vaccination (n=3). 
Of the 37 patients who had at least one vaccination 
before seizure onset, eight had their ﬁ rst seizure after 
Figure 1: Timing of ﬁ rst seizure and DTP vaccination
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the ﬁ rst immunisation (3 vaccination-proximate and 
5 vaccination-distant), 16 after the second (7 vaccination-
proximate and 9 vaccination-distant), and 13 after the 
third (2 vaccination-proximate and 11 vaccination-
distant). The diﬀ erences in proportions of patients in the 
vaccination-proximate group compared with the 
vaccination-distant group for each of the vaccinations 
was not signiﬁ cant (Fisher’s exact p=0·23). Whole-cell 
(as opposed to acellular) pertussis vaccine was given to 
four of 11 patients in the vaccination-proximate group 
and eight of 26 patients in the vaccination-distant group 
(Fisher’s exact p=0·27; data missing for one patient in 
the vaccination-proximate group and two in the 
vaccination-distant group).
The mean age at onset of Dravet syndrome was 
18·4 weeks (SD 5·9) in the vaccination-proximate group 
and 26·2 weeks (8·1) in the vaccination-distant group 
(diﬀ erence 7·8 weeks, 95% CI 2·6–13·1 weeks; t[38]=3·03, 
p=0·004; table  1). Comparison of other clinical 
characteristics suggested that there was no diﬀ erence 
between groups in the characteristics of the ﬁ rst seizure 
(documented fever, bilateral or unilateral convulsion, or 
status epilepticus), occurrence of other seizure types, 
presence of intellectual regression or intellectual disability, 
or syndromic diagnosis. 
Analysis of the SCN1A mutations in the 40  patients 
with validated data revealed 12  missense and 28  other 
mutations (18  truncation, 9 splice site mutations, and 
1 deletion of exons  21–26; ﬁ gure  2). Two mutations 
(IVS4+1G>A and S1516X) were found in patients in both 
the vaccination-proximate group and the vaccination-
distant group (webappendix).
From assessment of ﬁ gure 1, one could argue that 
patients with their ﬁ rst seizure 2–5 days after vaccination 
should also be included in the vaccination-proximate 
group. Post-hoc, the comparison of vaccination-proximate 
and vaccination-distant groups was rerun using an 
extended deﬁ nition of vaccination-proximate (seizure 
onset day 0–5). The mean age at onset was 20·5 weeks 
(SD 6·4) in the vaccination-proximate group and 
26·4 weeks (8·7) in the vaccination-distant group 
(diﬀ erence 5·9 weeks, 95% CI 0·9–11·0; p=0·02). Using 
this extended deﬁ nition, seven of 17 patients in the 
vaccination-proximate group and nine of 23 in the 
vaccination-distant group had intellectual regression 
(p=1·0), and 12 of 17 patients in the vaccination-proximate 
group and 15 of 23 in the vaccination-distant group had 
moderate or severe intellectual disability (p=1·0).
We also assessed whether age at onset or mutation type 
was associated with worse outcome, irrespective of 
proximity to vaccination. 13 of 40 patients had normal 
intellect or mild intellectual disability (mean age at onset 
21·3 weeks [SD 7·7]) and 27 of 40 patients had moderate 
or severe intellectual disability (25·1 weeks [8·4]; p=0·2). 
The mean age at onset was 21·9 weeks (8·6) for those 
with intellectual regression and was 25·2 weeks (8·0) for 
those without (p=0·2). There was no diﬀ erence between 
patients with missense mutations and those with other 
mutations in age at onset (other 23·6 weeks [7·0] vs 
missense 24·5 weeks [11·0]; p=0·8), moderate or severe 
intellectual disability (other 20 of 28 vs missense 7 of 12; 
Fisher’s exact p=0·5), or occurrence of regression (other 
13 of 28 vs missense 3 of 12; Fisher’s exact p=0·3). 
Most children receive three sequential identical 
vaccinations. However, in our sample the onset of 
seizures resulted in exclusion of the pertussis component 
from subsequent vaccinations in some patients. In a 
post-hoc analysis, we investigated the association between 
vaccination after seizure onset and intellectual disability. 
Complete vaccination data for the ﬁ rst year were available 
in 37 of 40 patients, 12 of whom had normal or mildly 
Vaccination-proximate 
(n=12)
Vaccination-distant 
(n=28)
p
First seizure
Age at onset (weeks) 18·4 (5·9) 26·2 (8·1) 0·004
Presence of fever* 4 (33%) 10 (37%)† 1·0
Initial convulsion type‡ 0·7
Bilateral 7 (58%) 18 (69%) ··
Unilateral 5 (42%) 8 (31%) ··
Status epilepticus§ 5 (45%)† 11 (41%)† 1·0
Subsequent seizure types
Tonic-clonic or secondarily generalised 12 (100%) 28 (100%) ··
Tonic 3 (25%) 5 (18%) 0·7
Atonic 2 (17%) 3 (11%) 0·6
Absence 8 (67%) 20 (71%) 1·0
Myoclonus 10 (83%) 25 (89%) 0·6
Hemiclonic 11 (92%) 23 (82%) 0·7
Focal¶ 11 (92%) 25 (89%) 1·0
Status epilepticus§ 11 (92%) 26 (93%) 1·0
Syndromic diagnosis
SMEI 8 (67%) 18 (64%)  1·0 
SMEB 4 (33%) 10 (36%) ··
Intellectual outcome
Regression 6 (50%) 10 (36%) 0·5
Intellectual disability 0·7**
None 0 1 (4%) ··
Mild 3 (25%) 9 (32%) ··
Moderate 3 (25%) 9 (32%) ··
Severe 6 (50%) 9 (32%) ··
SCN1A mutation type
Missense 2 (17%) 10 (36%) 0·3 
Other 10 (83%) 18 (64%) ··
Truncation (nonsense, frameshift) 8 10 ··
Splice site 1 8 ··
Intragenic copy number variation 1 0 ··
Data are mean (SD) or number (%). SMEI=severe myoclonic epilepsy of infancy. SMEB=severe myoclonic epilepsy of 
infancy borderline. *A temperature of greater than 38°C was regarded as febrile. †Details unavailable for one patient. 
‡Details unavailable for two patients in the vaccination-distant group. §A seizure lasting at least 30 min. ¶Does not 
include hemiclonic seizures. **2×2 analysis: no or mild intellectual disability versus moderate or severe intellectual 
disability.
Table 1: Clinical features, outcome measures, and type of SCN1A mutation
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impaired intellect and 25 of whom had moderate or 
severe intellectual disability (table 2). 15 of 37 patients 
had pertussis vaccinations after seizures began, and there 
was no evidence that subsequent vaccination was 
associated with a worse intellectual outcome (Fisher’s 
exact p=0·5)
Intellectual regression occurred in 14 of 37 children; six 
had further pertussis vaccination and eight did not. 
Further pertussis vaccination was administered in nine 
of 23 patients without intellectual regression. Subsequent 
pertussis vaccination was not associated with intellectual 
regression (no further vaccinations vs one or more further 
vaccinations; Fisher’s exact p=1·0).
Discussion 
About one-third of patients with Dravet syndrome had 
disease onset less than 2 days after vaccination, and the 
mean age at onset in these patients was signiﬁ cantly 
lower than that of patients whose disease onset was 
vaccination-distant. Universal vaccination in infancy is 
an emotive issue, in which science, societal views, and 
social policy are sometimes poorly aligned.1 At present, 
there is much attention on the debate regarding 
vaccination and autism;17–19 this attention is similar to the 
earlier intense debate regarding the role of pertussis 
vaccination and so-called vaccine encephalopathy. We 
previously reported a retrospective analysis in which 
12 of 14 patients with presumed vaccine encephalopathy 
in fact had previously unrecognised Dravet syndrome, 
11 of whom had mutations in SCN1A.5 This showed that 
vaccination was wrongly blamed as an acquired cause of 
a genetic disorder,20,21 and the hypothesis that vaccination 
was the causal factor in our cohort could be rejected. 
However, the possibility that vaccination triggered the 
onset of Dravet syndrome, causing a temporal shift 
(ie, brought forward an inevitable onset),22 or resulted in 
worse neurological outcome in these patients could not 
be excluded.
Recall bias can be a major factor in reporting of 
catastrophic disorders, and our impression was that 
certain cases of Dravet syndrome that were not clearly 
temporally associated with vaccination were nevertheless 
attributed to vaccination. Here, by examining a cohort of 
patients with Dravet syndrome who were not selected 
according to temporal relation to vaccination, we have 
conﬁ rmed the previous clinical reports that the onset of 
Dravet syndrome might occur shortly after vaccination.8,12 
In our cohort, in which recall bias was minimised by 
reliance on source records, 30% of patients with Dravet 
syndrome who had SCN1A mutations had seizure onset 
shortly after vaccination. 
We used a data-driven approach to identify days 0–1 as 
the at-risk period. The period of apparent vulnerability to 
onset of epilepsy after DTP vaccination has not been clearly 
deﬁ ned, although 24–72 h periods are generally used.7,23–27 
Our data was precise regarding the date, but not the hour, 
of vaccination and seizure onset. Because immunisations 
were likely to have been given in working hours, the at-risk 
period seems to be within 40 h of vaccination. 
The mean age at disease onset was 7·8 weeks earlier in 
the vaccination-proximate group than in the vaccination-
distant group, but all other clinical and outcome measures 
did not diﬀ er between groups (table 1). The mean age at 
onset in the vaccination-distant group was 26  weeks, 
which is similar to that quoted for patients with Dravet 
syndrome (5·5–6·0 months).8,28,29 Our ﬁ ndings show that, 
although vaccination might sometimes seem to trigger 
the onset of Dravet syndrome, there is no evidence that 
patients in the vaccination-proximate group had a 
diﬀ erent disorder from those in the vaccination-distant 
group. In particular, the similarity in clinical and outcome 
measures between patients in the vaccination-proximate 
group and those in the vaccination-distant group is not 
consistent with vaccination itself aﬀ ecting the severity of 
Figure 2: Schematic representation of SCN1A protein with mutations
SCN1A contains four domains (I–IV) each with six transmembrane segments. Segment four is the voltage sensor (blue) 
and segments ﬁ ve and six form the ion channel pore (grey). Truncation mutations (blue squares), missense mutations 
(red circles), and splice site mutations (green triangles) are shown. The exon 21–26 deletion identiﬁ ed in one patient is 
shown at the site that the deletion begins (green diamond).
 
 
 
 
 
 
 
 
 
 
 
 
 
IVS4+1G>A S1516X
Vaccination-proximate group (n=12)
COOH
COOH
NH2
NH2
Vaccination-distant group (n=28)
I II III IV
n Number of pertussis vaccinations after seizure 
onset (ﬁ rst year)
0 1 2 3
No or mild intellectual disability 12 6 2 3 1
Moderate or severe intellectual disability 25 16 7 2 0
Total 37 22 9 5 1
Fisher’s exact (no further vaccinations vs one or more further vaccinations) p=0·5.
Table 2: Relation of pertussis vaccination after seizure onset to intellectual disability
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the disorder. Using a diﬀ erent approach in a population 
cohort, Goodman and colleagues22 found evidence for a 
temporal shift of onset (but not of frequency) of infantile 
spasms in previously normal children after DTP or 
diphtheria and tetanus vaccination.
Molecular lesions also did not seem to diﬀ er in their 
type (missense versus other) or distribution within the 
protein between the vaccination-proximate and 
vaccination-distant groups (ﬁ gure 2). The same mutations 
occurred in both groups on two occasions, further 
highlighting the similarity of the groups.
Despite the absence of signiﬁ cant diﬀ erence, we 
wondered whether the higher number of non-missense 
mutations in the vaccination-proximate group could 
explain the earlier age at onset, but analysis of age at 
onset with respect to mutation type did not support this 
suggestion. We also examined whether earlier age at 
onset or presence of non-missense mutations were 
associated with intellectual disability or regression, and 
no associations were found. 
Seizure onset in Dravet syndrome commonly occurs in 
the setting of fever. Only one third of patients had fever 
documented with the initial seizure, suggesting that 
vaccination might work through an alternative 
mechanism to trigger seizure onset earlier than might 
have occurred otherwise. 
There are several limitations to this study. To study a 
homogeneous cohort, we assessed only patients with 
Dravet syndrome and SCN1A mutations who had been 
referred to the Epilepsy Research Centre, Melbourne, 
Australia. This approach might have resulted in some 
bias in the study. Also, our ﬁ ndings might not apply to the 
20–30% of patients with Dravet syndrome who do not 
have SCN1A mutations. Because of the problem of recall 
bias, we chose to include only patients with validated 
vaccination and onset data. This limited the number of 
patients we could include in the analyses, and thus type 2 
errors might have occurred. Finally, because our study 
was not a prospective evaluation with random assignment 
of vaccination, we cannot exclude the possibility that 
patients in the vaccination-distant group had an artiﬁ cially 
later age at onset because vaccination occurs at ﬁ xed 
times, typically at around 2, 4, and 6 months. However, 
this is unlikely because the mean age at onset in the 
vaccination-distant group was similar to that reported for 
patients with Dravet syndrome overall (ie, 6 months), 
whereas disease onset was at a mean of 18·4 weeks in the 
vaccination-proximate group. 
There is increasing interest in examining gene-environ-
ment interactions in clinical research. Our study design 
and absence of a control group of patients with Dravet 
syndrome who did not have DTP vaccinations precluded 
us from examining a gene-environment interaction. 
However, our observation of an environmental eﬀ ect 
(vaccination) temporally shifting the age at onset of an 
age-speciﬁ c genetic neurological disease with no apparent 
eﬀ ect on outcome suggests that Dravet syndrome would 
be an ideal model, both clinically and in experimental 
animals, with which to formally assess and examine the 
basis of such an interaction. If vaccination was withheld, 
the patients in the vaccination-proximate group would be 
expected to have had disease onset with the next 
substantial environmental trigger, be it fever, infection, 
or another stressor. 
We therefore conclude that there is no rational basis 
for withholding DTP immunisation for potentially lethal 
childhood diseases for fear of causing Dravet syndrome 
or injuring the brain by a direct or presumed immune-
mediated mechanism. The ﬁ nding that onset of seizures 
occurred after the ﬁ rst, second, or third vaccination 
argues against a major role for immune sensitisation in 
which an initial immune challenge (ie, vaccination) has 
no eﬀ ect but subsequent challenges have increasing 
eﬀ ects. Outcome was not inﬂ uenced by vaccination after 
clinical onset (table 2), and thus vaccination does not 
seem to cause brain damage, although this analysis was 
post hoc and would ideally require conﬁ rmation in a 
prospective study. 
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